| 1889-08-15 |
Eisai's founder, Toyoji Naito, is born on August 15 in Ito, Fukui, Japan. |
| 1905 |
Toyoji leaves his village at age 15, heading west to find employment in Osaka. |
| 1906 |
Toyoji is employed at Winkel Shokai in Kobe, taking night courses in foreign languages and bookkeeping. |
| 1909 |
Toyoji leaves Winkel Shokai after being drafted into the Japanese Imperial Guard. |
| 1911 |
After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe. |
| 1914 |
World War I begins. |
| 1915 |
Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd. |
| 1917 |
Toyoji embarks on a seven-month business tour of India and Southeast Asia. |
| 1918 |
World War I ends. |
| 1921 |
Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil Castalol and analgesic cream Salomethyl. |
| 1923 |
The Great Kanto Earthquake strikes, causing Tanabe Motosaburo Store Co., Ltd. to fall on hard times, including the main store in Tokyo burning down. |
| 1924 |
Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, Animasa. Toyoji coins the term for 'high blood pressure' in its ad campaign. |
| 1933 |
A Salomethyl newspaper ad created by Toyoji wins the Best Advertisement Award in Japan's Society for the Promotion of Newspaper Advertising. |
| 1936 |
Sakuragaoka Laboratory Co., Ltd. is established as a limited partnership in Tokyo. |
| 1937 |
Toyoji travels abroad to observe pharmaceutical industries in Europe and the United States. |
| 1938 |
Nihon Eisai is established, focusing on in-house R&D to create new medicines. |
| 1938 |
Sakuragaoka Laboratory Co., Ltd. launches vitamin E product Juvela and Japan's first sanitary tampon Sampon. |
| 1939 |
World War II begins. |
| 1941 |
Nihon Eisai Co., Ltd., the predecessor of Eisai, is established in Saitama. |
| 1944 |
Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merge under the name Nihon Eisai Co., Ltd. |
| 1945 |
World War II ends. |
| 1950 |
Nihon Eisai Co., Ltd.'s contraceptive suppository Sampoon receives official approval from the Japanese government. |
| 1952 |
Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product Chocola BB Tablets and motion sickness remedy Travelmin. |
| 1955 |
The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd. |
| 1957 |
Eisai rolls out its first three-year mid-term plan. Its Head Office building in Tokyo is completed. |
| 1961 |
Eisai opens its Taipei Office in Taiwan and is listed on the Tokyo and Osaka Stock Exchanges. |
| 1964 |
Toyoji Naito receives the Japan Marketing Award. The Tokyo Olympics take place. |
| 1966 |
The Kawashima Plant in Gifu is completed. Toyoji Naito is appointed chairman, Yuji Naito as president, and a three-tier director system is introduced. |
| 1969 |
Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan. |
| 1970 |
PT Eisai Indonesia is established as a manufacturing and sales subsidiary in Indonesia. |
| 1971 |
Toyoji Naito opens the Naito Museum of Pharmaceutical Science and Industry in Gifu. |
| 1973 |
The first oil crisis occurs due to conflict in the Middle East. |
| 1974 |
Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established. Neuquinon is launched in Japan. |
| 1977 |
Juvelux, a vitamin E product, is launched in Japan. |
| 1978 |
Founder Toyoji Naito passes away at age 89. |
| 1979 |
Eisai Asia Regional Services Pte. Ltd. is established in Singapore. |
| 1981 |
Eisai U.S.A. Inc. is established in California, and the Misato Plant begins pharmaceutical manufacturing in Saitama. |
| 1982 |
The Tsukuba Research Laboratories open in Ibaraki. |
| 1983 |
Eisai Chemical Co., Ltd. (now Kashima Plant) is established in Ibaraki for API manufacturing. |
| 1984 |
Gastritis and gastric ulcer treatment Selbex is launched in Japan. |
| 1987 |
Eisai supports healthcare awards and establishes the Boston Research Institute in Massachusetts. |
| 1988 |
President Yuji Naito steps down, Haruo Naito becomes president; Eisai America and Europe subsidiaries are established. |
| 1989 |
Eisai Machinery GmbH in Germany and Eisai (Thailand) Marketing Co., Ltd. are established. |
| 1990 |
Eisai London Research Laboratories is established; Japan's bubble economy bursts. |
| 1991 |
Eisai Hong Kong Co., Ltd. and Beijing Representative Office are established; Shenyang joint venture is formed; Eisai celebrates 50th anniversary. |
| 1992 |
Eisai adopts current mission and objectives; Eisai Corporation of North America is established. |
| 1995 |
Eisai Inc. in the US, Eisai Ltd. in the UK, and Eisai Deutschland GmbH in Germany are established. |
| 1996 |
Eisai S.A. in France and Eisai Suzhou Pharmaceutical Co., Ltd. in China are established. |
| 1997 |
KAN Research Institute in Osaka, Eisai Korea Inc., and North Carolina Plant are established; Aricept and Pariet launched internationally. |
| 1998 |
Aricept launched in France; Pariet launched in Germany and UK. |
| 1999 |
Pariet launched as AcipHex in the US; Aricept launched in Japan. |
| 2001 |
The 9/11 terrorist attacks occur; Eisai Farmacéutica S.A. established in Madrid. |
| 2002 |
Eisai Medical Research Inc. established; adopts 'Company with Committees' system. |
| 2004 |
Eisai Europe Ltd. established in London; Eisai Pharmaceuticals India Pvt. Ltd. in Mumbai. |
| 2005 |
Eisai S.r.l. in Italy, Pharma AG in Switzerland, and other subsidiaries established; Yuji Naito passes away. |
| 2006 |
Eisai launches 'Dramatic Leap Plan'; new subsidiaries in Australia, Singapore, Portugal, and others established. |
| 2007 |
Eisai Manufacturing Ltd. established in UK; acquires Morphotek Inc. in US; new subsidiaries in India and Belgium. |
| 2008 |
Eisai acquires MGI Pharma; launches Humira in Japan. |
| 2009 |
Eisai establishes subsidiaries in Austria and UK; opens European Knowledge Centre; launches Equfina in Japan. |
| 2010 |
Eisai establishes subsidiaries in Canada and China; launches Halaven in US; signs WHO agreement. |
| 2011 |
Great East Japan Earthquake; launches sixth mid-term plan 'HAYABUSA'; establishes subsidiaries in Brazil and Mexico. |
| 2012 |
Signs London Declaration; launches Fycompa in Europe; Naito appointed FPMAJ president. |
| 2013 |
Establishes LLC in Moscow; co-establishes GHIT Fund; provides free lymphatic filariasis medicine to WHO. |
| 2014 |
Fycompa launched in US; Eisai China Holdings Ltd. established. |
| 2015 |
Lenvima launched in US, Japan, Europe; acquires Liaoning Tianyi Pharmaceutical. |
| 2016 |
Eisai launches 'EWAY2025'; establishes EA Pharma; launches Fycompa in Japan. |
| 2017 |
Joins partnership for NCDs; supports lymphatic filariasis elimination; collaborates with Biogen on Alzheimer's treatments. |
| 2018 |
Strategic collaboration for Lenvima with Merck; new Suzhou plant operational; Lenvima launched in China. |
| 2019 |
Eisai G2D2 in Massachusetts begins operation; launches Equfina in Japan; launches Fycompa and Halaven in China. |
| 2020 |
WHO declares COVID-19 a pandemic; launches brain health tool NouKNOW; DAYVIGO in US and Japan; establishes Vietnam subsidiary and Shanghai health company. |
| 2021 |
Launch of eighth mid-term plan 'EWAY Future & Beyond'; ADUHELM approved and launched in US; enters collaboration with Bristol-Myers Squibb; celebrates 80th anniversary. |
| 2022 |
Amends ADUHELM collaboration; makes Arteryex subsidiary; establishes subsidiaries in South Africa; signs Kigali Declaration; launches DHBL R&D organization. |
| 2023 |
LEQEMBI granted accelerated and traditional FDA approval; funds third phase of GHIT; establishes Theoria Technologies in Tokyo; launches LEQEMBI in Japan. |
